Image courtesy of Dr. Stephen Plymate, University of Image courtesy of Dr. Stephen Plymate, University of
Product Details Product Name Anti-Androgen Receptor (AR-V7 specific) Rabbit Monoclonal Antibody, Clone RM7 Product Description Rabbit monoclonal to Androgen Receptor (AR-V7 specific), ARv7 Splice Variant Catalog No. 31-1109-00;
31-1109-02 Clone Name RM7 Product Data Sheet Anti-Androgen Receptor (AR-V7 specific) Rabbit Monoclonal Antibody Data Sheet RM7
Biotinylated Anti-Androgen Receptor (AR-V7 specific) Rabbit Monoclonal Antibody Data Sheet RM7 Specificity RM7 reacts to androgen receptor splice variant 7 (AR-V7). No cross reactivity with wild type androgen receptor. Immunogen A peptide corresponding to AR splice variant 7 Application Immunohistochemistry
Immunocytochemistry
Immunoprecipitation
Western Blot
Chromatin IP
Circulating Tumor Cells
Flow Cytometry Species Reactivity Human Conjugate None Intended Use Research Use Only . Properties Form Liquid Storage Instructions Store at -20.0°C Stability Stable for 1 Year at -20.0°C from date of receipt Storage Buffer 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide Volume/Item Size 100 µL;
Biotinylated 50 µL Purity Protein A affinity purified from an animal origin–free culture supernatant Clone Type Monoclonal Isotype Rabbit IgG Usage Immunohistochemistry (IHC): 1:500 – 1:1000 dilution;
Immunocytochemistry (ICC): 1:100 – 1:1000 dilution;
Western Blot (WB): 1:500 – 1:1000 dilution.
References for ARv7 Splice Variant antibody [RM7] Sowalsky AG et al AR-V7 in Primary Prostate Cancer. MedRxiv. (2022), 10.1101/2022.03.10.22271799. WB, IHC; Human. Read more (AR-V7 in Primary Prostate Cancer)
Hu Qet al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA BIOLOGY. (2021), 10.1080/15476286.2021.1983287. WB; Human. Read more (PubMed: 34592899)
Brady L et al Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. (2021), 10.1038/s41467-021-21615-4. IHC; Human. Read more (PubMed: 33658518)
Sugiura M et al. Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl Oncol. (2020), 10.1016/j.tranon.2020.100915. WB; Human. Read more (PubMed: 33096335)
Xu S et al. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer Res. (2020), 10.1158/0008-5472.CAN-20-0233. WB; Human. Read more (PubMed: 32522824)
Yoshizawa A et al. Combined a-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7epositive prostate cancer cells.. Prostate International. (2020), 10.1016/j.prnil.2020.07.001. WB; Human. Read more (Prostate International)
Labib M et al. Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting. Nat Biomed Eng. (2020), 10.1038/s41551-020-0590-1. FC; Human. Read more (PubMed: 32719513)
Hirayama Y et al. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. (2020), 10.1002/1878-0261.12770. WB; Human. Read more (PubMed: 32734688)
Gjyrezi A et al. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. (2020), 10.1172/JCI132184. IHC; Human. Read more (PubMed: 32478682)
Nappi L et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. (2020), 10.1172/JCI130819. WB; Human. Read more (PubMed: 31845908)
Ylitalo EB et al. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. Prostate. (2020), 10.1002/pros.23935. IHC; Human. Read more (PubMed: 31799745)
Lu C et al. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer Prostatic Dis. (2020), 10.1038/s41391-020-0217-3. IHC; Human. Read more (PubMed: 32139878)
Berger A et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. (2019), 10.1172/JCI127961. WB; Human. Read more (PubMed: 31260412)
Sharp A et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol. (2019), 10.1016/j.eururo.2019.04.006. IHC; Human. Read more (PubMed: 31036442)
Zadra G et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. (2019), 10.1073/pnas.1808834116. IHC, WB; Human. Read more (PubMed: 30578319)
Sowalsky AG et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. (2018), 10.1158/0008-5472.CAN-18-0610. IHC, ISH; Human. Read more (PubMed: 29921690)
Cato L et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. (2019), 10.1016/j.ccell.2019.01.008. IHC-F, WB; Human. Read more (PubMed: 30773341)
Bai S et al. A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene. (2019), 10.1038/s41388-019-0768-8. WB; Human. Read more (PubMed: 30820039)
Sharp A et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. (2018) 10.1172/JCI122819. IHC-P, IP, WB; Human. Read more (PubMed: 30334814)
Zhao P et al. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. Asian J Urol. (2018), 10.1016/j.ajur.2018.09.003. WB, IHC-P; Human. Read more (Asian J Urol. AJUR244)
Russo JW et al. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. (2018), 10.1158/0008-5472.CAN-18-0687. IHC-P; Human. Read more (PubMed: 30242112)
Yang RK et al. Expression pattern of androgen receptor and AR-V7 in androgen deprivation therapy naïve salivary duct carcinomas. Hum Pathol. (2018), 10.1016/j.humpath.2018.09.009. IHC-P; Human. Read more (PubMed: 30267779)
Lawrence MG et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol. (2018) 10.1016/j.eururo.2018.06.020. IHC-P; Human. Read more (PubMed: 30049486)
Kallio HML et al. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. (2018) 10.1038/s41416-018-0172-0. IHC-P; Human. Read more (PubMed: 29988112)
Zhao Pet al. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma by immunohistochemistry. American Association for Cancer Research. (2018) 10.1158/1538-7445.AM2018-2640. IHC-P; Human. Read more (AACR 2018 Abstracts: 2640)
Miao L et al. Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res. (2017) 10.1158/0008-5472.CAN-16-2169. WB; Human. Read more (PubMed: 28302679)
Moon SJ et al. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. Oncogene (2018) 10.1158/0008-5472.CAN-16-2169. WB; Human. IP; Human. ChIP; Human. Read more (PubMed: 29249800)
Zhu Y et al. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol. (2017) 10.1016/j.eururo.2017.08.009. WB; Human. IHC-P; Human. Read more (PubMed: 28866255)
Luo J et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. (2017) 10.1016/j.eururo.2017.11.038. WB; Human. IHC-P; Human. ChIP; Human. Read more (PubMed: 29258679)
J Luo et al. Noninvasive Detection of AR-FL/AR-V7 as a Predictive Biomarker for Therapeutic Resistance in Men with Metastatic Castration-Resistant Prostate Cancer. U.S. Army Medical Research and Materiel Command (2018) AWARD NUMBER: W81XWH-15-2-0050. WB, IHC, IP, ChIP; Human. Read More Protocols ARv7 ICC Protocol
ARv7 IHC Protocol Product Images
Western Blot analysis of 22RV1, DU145, and PC-3 whole cell
lysates, using anti-AR-V7 rabbit monoclonal Antibody Clone
RM7, showed endogenous AR-V7 expressed in 22RV1 cells.
Immunocytochemical staining of 22RV1 and PC-3 cells,
using anti-AR-V7 rabbit monoclonal Antibody Clone RM7 (red).
Actin filaments have been labeled with fluorescein phalloidin (green).
Immunohistochemical staining of formalin fixed and paraffin
embedded 22RV1, DU145 sections.
Immunohistochemical staining of formalin fixed and paraffin
embedded (FFPE) bone metastasis prostate cancer. Clinically
validated to be Positive for ARv7.
Washington, Washington, US
Immunohistochemical staining of formalin fixed and paraffin embedded (FFPE) bone metastasis prostate cancer. Clinically
validated to be Negative for ARv7.
Washington, Washington, US
Western Blot analysis of 22RV1 whole cell lysates, using anti-Androgen Receptor (N-term) antibody (Clone RM254),
anti-Androgen Receptor (C-term) antibody (Clone RM255),
and anti-Androgen Receptor (ARv7 specific) antibody
(Clone RM7), showed full length androgen receptor and splice variants expressed in 22RV1 cells.
Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7]
![Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7]](https://www.biotrend.com/en/upload/-img-lapin1.png)
Cat# 31-1109-00
Size : 100ul
Brand : RevMab Biosciences
Contact local distributor :
Phone : +1 850 650 7790
Rabbit monoclonal to Androgen Receptor (AR-V7 specific),
ARv7 Splice Variant
100 µL Standard, 50 µL Biotin Conjugate
You might also be interested by the following products:
Cat#
Description
Cond.
Price Bef. VAT
